Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 73, Issue 24, 2010, Pages 1665-1677

  Gallagher, Carolyn M ^a,b   Goodman, Melody S ^b,c  

^a PhD Program in Population Health and Clinical Outcomes Research   (United States)

^b Department of Preventive Medicine ^*  (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENT; ARTICLE; AUTISM; CAUCASIAN; CHILD; CONTROLLED STUDY; EDUCATIONAL STATUS; FAMILY LIFE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN CARE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; UNITED STATES; VACCINATION;

AUTISTIC DISORDER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH SURVEYS; HEPATITIS B VACCINES; HISPANIC AMERICANS; HUMANS; IMMUNIZATION SCHEDULE; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MODELS, BIOLOGICAL; NATIONAL HEALTH PROGRAMS; RISK FACTORS; SOCIOECONOMIC FACTORS; THIMEROSAL; UNITED STATES;

EID: 78249243424     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2010.519317     Document Type: Article

References (68)

1. American Academy of Pediatrics and U. S. Public Health Service. 1999. Joint Statement of the American Academy of Pediatrics (AAP) and the United States Public Health Services (USPHS). Pediatrics 104:568-569.
2. Adams, J. B., Romdalvik, J., Ramanujam, V. M. S., and Legator, M. S. 2007. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J. Toxicol. Environ. Health A 70:1046-1051.
3. Ashwood, P., and Van de Water, J. 2004 Is autism an autoimmune disease? Autoimmun. Rev. 3:557-562.
4. Ashwood, P., Wills, S., and Van de Water, J. 2006. The immune response in autism: a new frontier for autism research. J. Leukocyte Biol. 80:1-15.
5. Austin, D. W., and Shandley, K. 2008. An investigation of porphyrinuria in Australian children with autism. J. Toxicol. Environ. Health A 71:1349-1351.
6. Bailey, D. B., Hebbeler, D., Scarborough, A., Spike, D., and Mallik, S. 2004. First experiences with early interventions: A national perspective. Pediatrics 113:887-896.
7. Ball, L. K., Ball, R., and Pratt, R. D. 2001. An assessment of thimerosal use in childhood vaccines. Pediatrics 107:1147-1154.
8. Bhasin, T. K., and Schendel, D. 2007. Sociodemographic risk factors for autism in a U. S. metropolitan area. J. Autism Dev. Disorders 37:667-677.
9. Bialek, S. R., Bower, W. A., Novak, R., Helgenberger, L., Auerbach, S. B., Williams, I. T., and Bell, B. P. 2008. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr. Infect. Dis. J. 27:881-885.
10. Bolton, P., Holt, E., Ross, A., Hughart, N., and Guyer, B. 1998. Estimate vaccination coverage using parental recall, vaccination cards and medical records. Public Health Rep. 113:521-526.
11. Cavagnaro, A. T. 2009. California Department of Developmental Services. Autistic spectrum disorders, Changes in the California caseload, An update: June 1987-June 2007. Updated 2009 July 21; accessed 2009 October 31. http://www.dd.ca.gov/autism/docs/Autism/home.cfr
12. Centers for Disease Control. 1991. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm. Rep. 40 (RR-13): 1-25.
13. Centers for Disease Control. 2008. Timeline: Thimerosal in vaccines (1999-2008). Accessed 2009 May 10. http://www.cispimmunize.org
14. Croen, L. A., Grether, J. K., and Selvin, S. 2002. Descriptive epidemiology of autism in a California population: Who is at risk? J. Autism Dev. Disorders 32:217-224.
15. Demirjian, A., and Levy, O. 2009. Safety and efficacy of neonatal vaccination. Eur. J. Immunol. 39:36-46.
16. Dombkowski, K. J., Lantz, P. M., and Freed, G. L. 2004. Risk factors for delay in age-appropriate vaccination. Public Health Rep. 119:144-155.
17. Enstrom, A. M., Onore, C. E., Van de Water, J. A., and Ashwood, P. 2009. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav. Immun. doi: 10.1016/j.bbi.2009.08.001.
18. Euler, G. L., Wooten, K. G., Baughman, A. L., and Williams, W. W. 2003. Hepatitis B surface antigen prevalence among pregnant women in urban areas: Implications for testing, reporting, and preventing perinatal transmission. Pediatrics 111:1192-1197.
19. EUVAC. NET. 2010. EUVAC. NET, A surveillance community network for vaccine preventable infectious diseases. http://www.euvac.net/graphics/euvac/ background.htm. Accessed 7 January 2010.
20. Evans, A. A., and London, W. T. 1999. Letters: Hepatitis B vaccine and liver problems in U. S. children less than 6 years old. Epidemiology 10:790-791.
21. Fatemi, S. H., Reutiman, T. H., Folsom, T. D., and Turas, P. D. 2009. GABA (A) receptor downregulation in brains of subjects with autism. J. Autism Dev. Disorders 39:223-230.
22. Feikema, S. M., Klevens, R. M., Washington, M. L., Barker, L. 2000. Extraimmunization among US children. JAMA 283:1311-1317.
23. Filipek, P. A., Accardo, P. J., Ashwal, S., Baranek, G. T., Cook, E. H., Dawson, G., Gordon, B., Gravel, J. S., Johnson, C. P., Kallen, R. J., Levy, S. E., Minshew, N. J., Ozonoff, S.
24. Prizant, B. M., Rapin, I., Rogers, S. J., Stony, W. L., Teplin, S. W., Tuchman, R. F., and Volkmar, F. R. 2000. Practice parameter: Screening and diagnosis of autism: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 55:468-479.
25. Fisher, M. A., and Eklund, S. A. 1999. Hepatitis B vaccine and liver problems in U. S. children less than 6 years old, 1993 and 1994. Epidemiology 10:337-339.
26. Fisher, M. A., Eklund, S. A., James, S. A., and Lin, X. 2001. Adverse events associated with hepatitis B vaccine in US children les than six years of age, 1993 and 1994. Ann. Epidemiol. 11:13-21.
27. Fombonne, E. 2003. Epidemiological surveys of autism and other pervasive developmental disorders: An update. J. Autism Dev. Disorders 33:365-382.
28. Gallagher, C., and Goodman, M. 2008. Hepatitis B triple series vaccine and developmental disability in US children aged 1-9 years. Toxicol. Environ. Chem. 90:997-1008.
29. Giambi, C., Bella, A., Barale, A., Montu, D., Marchisio, M., Oddone, M., Zito, S., Rapicetta, M., Chionne, P., Madonna, E., and degli Atti, M. L. 2008. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect. Dis. 8:100. Accessed 22 May 2009, http://www.biomedcentral.com/1471-2334/8/100
30. Geier, D. A., and Geier, M. R. 2007. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J. Toxicol. Environ. Health A. 70:1723-1730.
31. Gupta, S., Aggarwal, S., Rashanravan, B., and Lee, T. 1998. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J. Neuroimmunol. 85:106-109.
32. Hemdan, N. Y. A., Emmrich, F., Faber, S., Lehmann, J., and Sack, U. 2007. Alterations of Th1/Th2 reactivity by heavy metals. Ann. NY Acad. Sci. 1109:129-137.
33. Hertz-Picciotto, I., and Delwiche, L. 2009. The rise in autism and the role of age at diagnosis. Epidemiology 20:84-90.
34. Hillman, R. E., Kanafani, N., Takahashi, T. N., and Miles, J. H. 2000. Prevalence of autism in Missouri. MO Med. 97:159-163.
35. Institue of Medicine. 2004. IOM imunization safety review: Vaccines and autism, 2004. Washington, DC: National Academy of Sciences, The National Academy Press. Accessed May 10, 2009. http://www.iom.edu/?id=20155&redirect=0
36. James, S. J., Cutler, P., Melnyk, S., Jernigan, S., Janak, L., Gaylor, D. W., and Neubrander, J. A. 2004. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr. 80:1611-11617.
37. Jyonouchi, H., Sun, S., and Le, H. 2001. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J. Neuroimmunol. 120:170-179.
38. Kaplan, M., Herschel, M., Hammerman, C., Hoyer, J. D., and Stevenson, D. K. 2004. Hyperbilirubinemia among African American, glucose-6-phosphate dehydroge nase-deficient neonates. Pediatrics 114: e213-e219.
39. Kern, J. K., and Jones, A. M. 2006. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J. Toxicol. Environ. Health B 9:485-499.
40. Kogan, M. D., Blumberg, S. J., Schieve, L. A., Boyle, C. A., Perrin, J. M., Ghandour, R. M., Singh, G. K., Strickland, B. B., Trevathan, E., and van Dyck, P. C. 2009. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124:1395-1403.
41. Lewis, E., Shinefield, H. R., Woodruff, B. A., Black, S. B., Destefano, F., Chen, R. T., Ensor, R., and Vaccine Safety Datalink Workgroup. 2001. Safety of neonatal hepatitis B vaccine administration. Pediatr. Infect. Dis. J. 20:1049-1054.
42. Li, X., Chauhan, A., Sheikh, A. M., Patil, S., Chauhan, V., Li, X. M., Ji, L., Brown, T., and Malik, M. 2009. Elevated immune response in the brain of autistic patients. J. Neuroimmunol. 207:111-116.
43. Mandell, D. S., Wiggins, L. D., Carpenter, L. A., Daniels, J., DiGuiseppi, C., Durkin, M. S., Giarelli, E., Morrier, M. J., Nicholas, J. S., Pinto-Martin, J. A., Shattuck, P. T., Tomas, K. C., Yeargin-Allsopp, M., and Kirby, R. S. 2009. Racial/ethnic disparities in the identification of children with autism spectrum disorders. Am. J. Public Health 99:493-498.
44. Maimburg, R. D., Schendel, V. M., Bech, B H., Olsen, J., and Thorsen, P. 2008. Neonatal jaundice: A risk factor for infantile autism? Paediatr. Perinat. Epidemiol. 22:562-568.
45. Marodi, L. 2002. Down-regulation of Th1 responses in human neonates. Clin. Exp. Immunol. 128:1-2.
46. Marques, R. C., Dorea, J. G., Manzatto, A. G., Bastos, W. R., Bernardi, J. V. E., and Malm, O. 2007. Time of perinatal immunization, thimerosal exposure and neurodevelopment at 6 months in breastfed infants. Acta Paediatr. 96:864-868.
47. May-Benson, T. A., Koomar, J. A., and Teasdale, A. 2009. Incidence of pre-, peri-, and post-natal birth and developmental problems of children with sensory processing disorder and children with autism spectrum disorder. Front. Integr. Neurosci. 3:1-12.
48. Mell, L. K., Ogren, D. S., Davis, R. L., Mullooly, J. P., Black, S. B., Shinefield, H. R., Zangwill, K. M., Ward, J. I., Marcy, S. M., Chen, R. T.: Centers for Disease Control and Prevention Vaccine Safety Datalink Project. 2005. Compliance with national immunization guidelines for children younger than 2 years, 1996-1999. Pediatrics 115:461-467.
49. Mikaeloff, Y., Caridade, G., Suissa, S., and Tardieu, M. 2009. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 72:873-880.
50. Molloy, C. A., Morrow, A. L., Meinzen-Derr, J., Dawson, G., Bernier, R., Dunn, M., Hyman, S. L., McMahon, W. M., Goudie-Nice, J., Hepburn, S., Minshew, N., Rogers, S., Sigman, M., Spence, M. A., Tager-Flusberg, H., Volkmar, F. R., and Lord, C. 2006. Familial autoimmune thyroid disease as a risk factor for regression in children with autism spectrum disorder: A CPEA study. J. Autism Dev. Disorders 36:317-324.
51. Nataf, R., Skorupka, C., Amet, L., Lam, A., Springbett, A., and Lathe, R. 2006. Porphyrinuria in childhood autistic disorder: Implications for environmental toxicity. Toxicol. Appl. Pharmacol. 214:99-108.
52. Naleway, A. L., Belongia, E. A., Donahue, J. G., Kieke, B. A., Glanz, J. M., for the Vaccine Safety Datalink 2009. Risk of immune hemolytic anemia in children following immunization. Vaccine 27:7394-7397.
53. National Center for Health Statistics. 2002a. Data file documentation, National Health Interview Survey, 1997-2002. National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD. UpdatedOctober 5, 2009; accessed October 31, 2009. http://www.cdc.gov/nchs/nhis/ quest-data-related-1997-forward.htm
54. National Center for Health Statistics. 2002b. Immunization core questions, Basic module, Version 00.3. National Health Interview Survey. National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD. Updated October 5, 2009; accessed October 31, 2009. http://www.cdc.gov/nchs/nhis/quest-data-related-1997-forward.htm
55. Ozonoff, S., Williams, B. J., and Landa, R. 2005. Parental report of early development of children with regressive autism: The delays-plus-regression phenotype. Autism 5:461-486.
56. Price, C., Robertson, A., Goodson, B. 2009. Thimerosal and autism. Technical report. Vol I. Bethesda, MD: Abt Associates Inc.
57. Price, C. S., Thompson, W. W., Goodson, B., Weintraub, E. S., Croen, L. A., Hinrichsen, V. L., Marcy, M., Robertson, A., Eriksen, E., Lewis, E., Bernal, P., Shay, D., Davis, R. L., DeStefano F. 2010. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics [published online Sep. 13, 2010; DOI: 10.1542/peds.2010-0309.
58. Rice, C. 2007. Prevalence of autism spectrum disorders-Autism and developmental disabilities monitoring network, Six sites, United States, 2000. MMWR Surveill. Summ. 56:1-11.
59. Rice, C., Schendel, D., Cunniff, C., and Doernberg, N. 2004. Public health monitoring of developmental disabilities with a focus on the autism spectrum disorders. Am. J. Med. Genet. 125 C: 22-27.
60. Singh, V. K. 2009. Phenotypic expression of autoimmune autistic disorder (AAD): A major subset of autism. Ann. Clin. Psychiatry 21:148-161.
61. Singh, V. K., and Hanson, J. 2006. Assessment of mketallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal. Pediatr. Allergy Immunol. 17:291-296.
62. Suarez, L., Simpson, D. M., and Smith, D R. 1997. Errors and correlates in parental recall of child immunizations: Effects on vaccination coverage estimates. Pediatrics 99: E3.
63. Sweeten, T. L., Bowyer, S. L., Posey, D. J., Halberstadt, G. M., and McDougle, C. J. 2003. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 112: e420-424.
64. Tuchman, R., Moshe, S. L., and Rapin, I. 2009. Convulsing toward the pathophysiology of autism. Brain Dev. 31:95-103.
65. Van Damme, P., van Herck, K., and Meus, A. 2000. Letters: Hepatitis B vaccine is not associated with liver problems in U. S. children less than 6 years old. Epidemiology 11:364.
66. Verstraeten, T., Davis, R. L., DeStefano, F., Lieu, T. A., Rhodes, P. H., Black, S. B., Shinefield, H., Chen, R. T., and Vaccine Safety Datalink Team. 2003. Safety of thimerosalcontaining vaccines: A two-phased study of computerized health maintenance organization databases. Pediatrics 112:1039-1048.
67. Wang, K., Zhang, H., Ma, D., Bucan, M., Glessner, J. T., Abrahams, B. S., Salyakina, D., Imielinski, M., Bradfield, J. P., Sleiman, P. M., Kim, C. E., Hou, C., Frackelton, E., Chiavacci, R., Takahashi, N., Sakurai, T., Rappaport, E., Lajonchere, C. M., Munson, J., Estes, A., Korvatska, O., Piven, J., Sonnenblick, L. I., Alvarez Retuerto, A. I., Herman, E. I., Dong, H., Hutman, T., Sigman, M., Ozonoff, S., Klin, A., Owley, T., Sweeney, J. A., Brune, C. W., Cantor, R. M., Bernier, R., Gilbert, J. R., Cuccaro, M. L., McMahon, W. M., Miller, J., State, M. W., Wassink, T. H., Coon, H., Levy, S. E., Schultz, R. T., Nurnberger, J. I., Haines, J. L., Sutcliffe, J. S., Cook, E. H., Minshew, N. J., Buxbaum, J. D., Dawson, G., Grant, S. F., Geschwind, D. H., Pericak-Vance, M. A., Schellenberg, G. D., and Hakonarson, H. 2009. Common genetic variants on 5p14.1 associated with autism spectrum disorders. Nature. doi: 10.1038/nature07999 [10 May 2009].
68. Young, H. A., Geier, D. A., and Geier, M. R. 2008. Thimerosal exposure in infants and neurodevelopmental disorders: An assessment of computerized medical records in the Vaccine Safety Datalink. J. Neurol. Sci. 271:110-118.